Table 5.
Univariate and multivariate analyses for overall survival.
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | B | HR (95% CI) | P value | |
| Therapy regimens | |||||
| Doublet chemotherapy | Reference | 0.417 | |||
| PD-1 inhibitor plus doublet chemotherapy | 1.224 (0.737-2.033) | 0.436 | |||
| Triplet regimen | 0.835 (0.524-1.332) | 0.450 | |||
| Age (years) | |||||
| <30 | Reference | 0.809 | |||
| ≥30 | 0.937 (0.555-1.583) | ||||
| Sex | |||||
| Male | Reference | 0.279 | |||
| Female | 1.246 (0.837-1.856) | ||||
| Tumor location | |||||
| Gastric cardia | Reference | 0.413 | |||
| Gastric body | 0.735 (0.437-1.238) | 0.247 | |||
| Gastric antrum | 0.675 (0.363-1.253) | 0.213 | |||
| Histological classification | |||||
| High-to-moderate differentiation | Reference | 0.086 | Reference | 0.190 | |
| Poor differentiation | 1.835 (0.917-3.670) | 0.472 | 1.603 (0.791-3.249) | ||
| PS score | |||||
| 0 | Reference | <0.001 | Reference | <0.001 | |
| ≥1 | 3.768 (2.489-5.704) | 1.333 | 3.791 (2.479-5.798) | ||
| PD-L1 expression | |||||
| Positive | Reference | 0.950 | |||
| Negative | 0.929 (0.508-1.698) | 0.811 | |||
| Unknown | 0.919 (0.545-1.551) | 0.751 | |||
| Peritoneal metastasis | |||||
| Yes | Reference | 0.314 | |||
| No | 0.819 (0.555-1.208) | ||||
| Number of metastatic lesions | |||||
| 1 | Reference | 0.030 | Reference | 0.014 | |
| ≥2 | 1.583 (1.047-2.394) | 0.535 | 1.707 (1.116-2.611) | ||
| Familial history of tumor | |||||
| Yes | Reference | 0.774 | |||
| No | 0.912 (0.487-1.708) | ||||
| Palliative surgery | |||||
| Yes | Reference | 0.173 | |||
| No | 1.390 (0.866-2.234) | ||||
| Later-line treatment of tumors | |||||
| Yes | Reference | 0.024 | Reference | 0.147 | |
| No | 1.681 (1.071-2.639) | 0.341 | 1.406 (0.887-2.230) | ||
| CEA level a | |||||
| ≤1.96 ng/mL | Reference | 0.366 | |||
| >1.96 ng/mL | 0.834 (0.562-1.236) | ||||
| CA19-9 level a | |||||
| ≤18.08 U/mL | Reference | 0.799 | |||
| >18.08 U/mL | 0.951 (0.644-1.404) | ||||
PD-1, programmed death 1; PS, performance status; PD-L1, programmed cell death-Ligand 1; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen (CA) 19–9; HR, hazard ratio; CI, confidence interval; B, beta coefficient.
a Take the median of this cohort as cut-off value.